Avanir Pharmaceuticals Earnings: Here’s Why Investors Don’t Like These Results
Avanir Pharmaceuticals (NASDAQ:AVNR) had a loss and missed Wall Street’s expectations, AND met the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 3.81%.
Avanir Pharmaceuticals Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.12 in the quarter versus EPS of $-0.13 in the year-earlier quarter.
Revenue: Rose 73.31% to $17.4 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Avanir Pharmaceuticals reported adjusted EPS loss of $0.12 per share. By that measure, the company missed the mean analyst estimate of $-0.09. It met the average revenue estimate of $17.4 million.
Quoting Management: “Avanir achieved a major milestone with the exciting news regarding the positive CHMP opinion for NUEDEXTA in Europe. This is a significant moment in the evolution of the company towards its goal of becoming a leading mid-cap biopharmaceutical company,” said Keith A. Katkin, president and CEO of Avanir. “Additionally, we continue to execute in the U.S. as demonstrated by our commercial and clinical progress. We enter the second half of fiscal 2013 with strong momentum, a broad CNS pipeline and a continued focus on building our business.”
Key Stats (on next page)…
Revenue increased 5.33% from $16.52 million in the previous quarter. EPS decreased to $-0.12 in the quarter versus EPS of $-0.09 in the previous quarter.
Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.02 to a loss $0.07. For the current year, the average estimate has moved down from a loss of $0.24 to a loss of $0.27 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)